Upstream Bio Inc (UPB) Quote

Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference

WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– Advancing Phase 2 clinical trials of verekitug in patients with severe asthma and CRSwNP – – Commenced startup for a Phase 2 clinical trial in COPD; on track for first patient to be dosed in H2...

Form SC 13D - General Statement of Acquisition of Beneficial Ownership

Form 4 - Statement of changes in beneficial ownership of securities

Upstream Bio Announces Closing of $293 Million Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus...

Form 8-K - Current report

Upstream Bio Announces Pricing of Upsized Initial Public Offering

WALTHAM, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus...